Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En registerstudie for å vurdere fotobiomodulasjon i tørr aldersrelatert makuladegenerasjon (EUROLIGHT) (EUROLIGHT)

21. september 2026 oppdatert av: LumiThera, Inc.

En multisenter-registerstudie for å vurdere sikkerheten og effektiviteten av fotobiomodulering hos deltakere med tørr aldersrelatert makuladegenerasjon (EUROLIGHT)

The purpose of this registry study is to collect real life data pertaining to the safety and clinical effectiveness of multi-wavelength photobiomodulation (PBM) as provided by the Valeda Light Delivery System in participants with dry age-related macular degeneration (AMD) in routine clinical practice. Data will be collected retrospectively and prospectively.

PBM involves the use of visible light to near infrared light (NIR) (500-1000 nanometers) produced by a laser or a non-coherent light source applied to the surface of the body to activate mitochondrial respiratory chain components, stabilize metabolic function, and promote cellular proliferation.

This registry study will be conducted in Europe, the US, and select other countries approved by their regulatory agency.

This registry study was initiated as a combined retrospective and prospective data collection effort. After the acquisition of LumiThera by Alcon Research, LLC in September 2025, the study was amended to prospectively collect data from U.S. sites starting in July 2026.

Studieoversikt

Status

Rekruttering

Intervensjon / Behandling

Detaljert beskrivelse

In this multi-center registry study, each qualifying eye will or will have been treated with the Valeda Light Delivery System for a total of nine short, non-invasive treatments over a three-to-five-week period and retreated every four to six months for a total of up to six rounds of treatment, as determined by the investigator.

Participants are considered to have completed the study if they complete at least one full treatment round with Optical Coherence Tomography (OCT) imaging collected post treatment. Participation may last up to 31 months, or as determined by the Investigator as the duration between treatment rounds and number of treatment rounds may vary by participant based on the progression of the disease as determined by the Investigator.

Studietype

Observasjonsmessig

Registrering (Antatt)

500

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • California
      • Beverly Hills, California, Forente stater, 90211
        • Har ikke rekruttert ennå
        • Retina Vitreous Associates Medical Group
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45242
        • Har ikke rekruttert ennå
        • Cincinnati Eye Institute
    • South Carolina
      • Charleston, South Carolina, Forente stater, 29414
        • Har ikke rekruttert ennå
        • Carolina Eyecare Physicians
    • Texas
      • McAllen, Texas, Forente stater, 78503
        • Rekruttering
        • Valley Retina Institute
    • Washington
      • Silverdale, Washington, Forente stater, 98383
        • Har ikke rekruttert ennå
        • Pacific Northwest Retina
      • Oslo, Norge, 0366
        • Aktiv, ikke rekrutterende
        • Institutt for Oyehelse

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Barn
  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Sannsynlighetsprøve

Studiepopulasjon

The patient population for this study will consist of a target of at least 25 male and female participants per site of any ethnic background and with a diagnosis of dry AMD by the Investigator or confirmed by the Investigator. The participant must meet all the inclusion criteria, have none of the exclusion criteria, and give their written Informed Consent to participate in this clinical study.

Only if the participant is interested in participating, s/he would be given the option to sign the study consent and start the study procedures, or if retrospectively signing the informed consent form, have their data used in the study.

Beskrivelse

Inclusion Criteria:

  1. Diagnosis or confirmation of diagnosis of dry AMD disease by Investigator;
  2. Able to communicate well with the Investigator and able to understand and comply with the requirements of the study;
  3. Informed of the nature of this study and has provided written, informed consent; (participants enrolled retrospectively will need to be contacted and sign an informed consent form prior to their data being used).

Exclusion Criteria:

  • US Sites Only: Center-involving geographic atrophy;
  • Neovascular maculopathy;
  • Use of any photosensitizing agent (e.g. topicals, injectables) activated by the Valeda Light Deliver System within 30 days prior to treatment without consulting participant's physician;
  • Known photosensitivity to yellow light, red light, or near infrared radiation (NIR), or has a history of light activated central nervous system disorders (e.g. epilepsy, migraine);
  • In the opinion of the Investigator, is unlikely to comply with the study protocol or has a history or current evidence of any condition that, in the opinion of the investigator, might interfere with the participant's involvement in the trial, or is not in the best interest of the participant.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: CASE_ONLY
  • Tidsperspektiver: OTHER

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Photobiomodulation (PBM)

Two alternating and sequential treatments with the Valeda Light Delivery System of 590 nm and 850 nm for 35 seconds, or a total of 70 seconds, followed by 660 nm for 90 seconds, or a total of 180 seconds

FDA-approved, multi-wavelength light delivery system for providing a pre-set treatment of pulsed light in 3 distinct wavelengths (PBM) to the participant's eye and retinal tissue through the open and closed eyelid.

The Valeda Light Delivery System is a CE Marked Class IIa device in Europe (Certificate # CE 653115) and a Class 2 device in the United States (DEN230083).

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Visual Acuity from Baseline at each Treatment Visit
Tidsramme: Baseline (Day 0) pre-treatment; up to Month 31/exit

Visual acuity will be assessed prior to any PBM treatment (baseline) and at each treatment visit after PBM was delivered.

Baseline (Day 0) pre-treatment; up to Month 31/exit
Number of Adverse Events Associated with PBM Treatment
Tidsramme: Up to Month 31/exit

The number of adverse events associated with PBM treatment will be reported.

Up to Month 31/exit

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: Sr. Principal Clinical Trial Operations, Surgical, Alcon Research, LLC

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. september 2023

Primær fullføring (Antatt)

1. november 2028

Studiet fullført (Antatt)

1. november 2028

Datoer for studieregistrering

Først innsendt

2. april 2024

Først innsendt som oppfylte QC-kriteriene

2. april 2024

Først lagt ut (Faktiske)

8. april 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

22. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

21. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • CSP006

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere